Emerging Trends in the Development of GLP 1 Receptor Agonists Biopharma PEG Survodutide PeptiFy Labs Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link In Chinese adults with overweight or obesity, once weekly #GLP glucagon agonist mazdutide, at a dose of 4 mg or 6 mg for 32 48 weeks, led to clinically relevant #weightloss in the Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors Nature Communications